In serological analyses by the SEREX (Serological analysis of expression cDNA libraries) technology, GLEA2 were found to frequently elicit immune responses in sera of GBM patients and acted as a prognostic biomarker for glioma [12]. This evidence concerns the gene PHF20 and glioma.